替吉奥与信迪利单抗在晚期胃癌治疗中的临床疗效和安全性研究  

Investigation on the clinical efficacy and safety of Tegafur and Sintilimab in the treatment of advanced gastric cancer

作　　者：李超明 LI Chaoming(Department of Oncology,Maoming People’s Hospital,Guangdong,Maoming 525000,China)

机构地区：[1]茂名市人民医院肿瘤科,广东茂名525000

出　　处：《中国医药科学》2023年第14期146-149,共4页China Medicine And Pharmacy

基　　金：广东省茂名市科技计划项目(2020082)。

摘　　要：目的探讨替吉奥与信迪利单抗联合用于晚期胃癌的治疗效果并评估其安全性。方法选取2020年1月至2022年8月于茂名市人民医院肿瘤科住院的晚期胃癌患者84例,依据是否联合使用PD-1/L1抑制剂将患者分成观察组(n=36)和对照组(n=48)。观察组接受替吉奥口服+信迪利单抗联合治疗,对照组仅给予替吉奥口服。比较两组患者一般资料、肿瘤治疗效果、不良反应率、治疗前后肿瘤标志物变化。结果观察组与对照组在性别、年龄、病理类型及TNM分期比较,差异无统计学意义(P>0.05)。观察组客观缓解率高于对照组,差异有统计学意义(P<0.05),两组不良反应总发生率比较差异无统计学意义(P>0.05),观察组治疗后肿瘤标志物癌胚抗原(CEA)、糖链抗原199(CA199)、肿瘤特异性生长因子(TSGF)低于对照组,差异有统计学意义(P<0.05)。结论替吉奥与信迪利联合用于晚期胃癌的化疗,可取得较好的抗肿瘤效果,值得临床进一步推广。Objective To investigate the therapeutic efficacy of Tegafur combined with Sintilimab in the treatment of advanced gastric cancer and evaluate its safety.Methods A total of 84 patients with advanced gastric cancer hospitalized in the Department of Oncology of Maoming People’s Hospital from January 2020 to August 2022 were included and divided into the observation group(n=36)and the control group(n=48)according to whether PD-1/L1 inhibitors were used in combination.The observation group was treated with the combined Tegafur(oral administration)and Sintilimab,while the control group was only treated with Tegafur(oral administration).The general data,therapeutic efficacy on tumor,incidence of adverse reactions(ADRs)and changes of tumor markers before and after treatment were compared between the two groups of patients.Results There were no statistically significant differences in gender,age,pathological type and TNM staging between the observation group and the control group(P>0.05).The objective remission rate in the observation group was higher than that in the control group,with statistically significant difference(P<0.05),and there was no statistically significant difference in the total incidence of ADRs between the two groups(P>0.05).After treatment,the tumor markers carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)and tumor specific growth factor(TSGF)in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).Conclusion The combination of Tegafur and Sintilimab in the chemotherapy of advanced gastric cancer can achieve relatively better anti-tumor efficacy.Therefore,it is worthy of further promotion in clinical practice.

关 键 词：替吉奥 信迪利单抗 晚期胃癌 临床疗效 安全性 

分 类 号：R735.2[医药卫生—肿瘤]